<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Research Foundation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22408627</article-id><article-id pub-id-type="pmc">3296064</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2012.00013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Low- vs High-Frequency Repetitive Transcranial Magnetic Stimulation as an Add-On Treatment for Refractory Depression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eche</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mondino</surname><given-names>Marine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haesebaert</surname><given-names>Frederic</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Saoud</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Poulet</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brunelin</surname><given-names>Jerome</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn001">*</xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Universit&#x000e9; de Lyon</institution><country>Lyon, France</country></aff><aff id="aff2"><sup>2</sup><institution>Universit&#x000e9; Lyon 1</institution><country>Lyon, France</country></aff><aff id="aff3"><sup>3</sup><institution>EA4615, Centre Hospitalier Le Vinatier</institution><country>Bron, France</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: William McDonald, Emory University School of Medicine, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Christopher A. Wall, Mayo Clinic, USA; Wonnei Caumo, Universidade Federal do Rio Grande do Sul, Brazil</p></fn><corresp id="fn001">*Correspondence: Jerome Brunelin, EA 4615, P&#x000f4;le EST, Centre Hospitalier Le Vinatier, 95 Boulevard Pinel, 69 677 Bron Cedex, France. e-mail: <email>jerome.brunelin@ch-le-vinatier.fr</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Neuropsychiatric Imaging and Stimulation, a specialty of Frontiers in Psychiatry.</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>3</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>3</volume><elocation-id>13</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Eche, Mondino, Haesebaert, Saoud, Poulet and Brunelin.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement"><license-p>This is an open-access article distributed under the terms of the <uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Non Commercial License</uri>, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.</license-p></license></permissions><abstract><p><bold>Objectives:</bold> Repetitive transcranial magnetic stimulation (rTMS) seems to be effective as an antidepressant, however, some confusion remains about the best parameters to apply and the efficacy of its association with pharmacological antidepressant treatments. <bold>Method:</bold> In a single blind randomized study 14 patients with unipolar resistant depression to one antidepressant treatment were enrolled to receive, in combination with venlafaxine (150&#x02009;mg), either 20 sessions of 10&#x02009;Hz rTMS (2000 pulses per session) applied over the left dorsolateral prefrontal cortex (DLPFC) or 20 sessions of 1&#x02009;Hz rTMS (120 stimulations per sessions) applied over the right DLPFC. <bold>Results:</bold> A similar antidepressant effect was observed in both groups with a comparable antidepressant delay of action (2&#x02009;weeks) and a comparable number of responders (MADRS&#x02009;&#x0003c;&#x02009;15) after 4&#x02009;weeks of daily rTMS sessions (66 vs 50%). <bold>Conclusion:</bold> Low- and high- frequency rTMS seems to be effective as an add-on treatment to venlafaxine as monotherapy in pharmacological refractory major depression (stage 1). Due to its short duration (one session of 1&#x02009;Hz rTMS lasts 4&#x02009;min vs 16 for 10&#x02009;Hz rTMS) and its safety, low frequency rTMS may be a useful alternative treatment for patients with refractory depression.</p></abstract><kwd-group><kwd>transcranial magnetic stimulation</kwd><kwd>dorsolateral prefrontal cortex</kwd><kwd>rTMS</kwd><kwd>venlafaxine</kwd><kwd>depression</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="17"/><page-count count="4"/><word-count count="2703"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Depression constitutes a major public health concern with a considerably high level of morbidity and mortality. Although antidepressant (AD) treatments have demonstrated their efficiency, a substantial number of depressed patients (50&#x02013;60%) respond only partially or not at all to at least one trial of an antidepressant medication (Steffens et al., <xref ref-type="bibr" rid="B15">1997</xref>) and close to 20% of these patients are refractory to any antidepressant medication (Fava, <xref ref-type="bibr" rid="B4">2003</xref>). Moreover, the clinical utility of antidepressant drugs is impaired by the delay in onset of their therapeutic action.</p><p>Most of recent studies as well as meta-analysis support an antidepressant effect of high frequency (HF) repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (LDLPFC; George et al., <xref ref-type="bibr" rid="B6">2010</xref>; for review: Brunelin et al., <xref ref-type="bibr" rid="B3">2007</xref>). However there remains some confusion about the best beneficial stimulation site to target as well as the best parameters to apply. While the impact of starting a combination between rTMS and an AD at the same time is still poorly studied, some authors support the hypothesis that this association could shorten the AD treatment delay of action (Poulet et al., <xref ref-type="bibr" rid="B11">2004</xref>; Rumi et al., <xref ref-type="bibr" rid="B13">2005</xref>). On the other hand, there is growing evidence that HF LDLPFC is as effective as low frequency (LF) rTMS applied to the right DLPFC (RDLPFC) in the treatment of depressive episode (H&#x000f6;ppner et al., <xref ref-type="bibr" rid="B7">2003</xref>; Isenberg et al., <xref ref-type="bibr" rid="B8">2005</xref>; Stern et al., <xref ref-type="bibr" rid="B16">2007</xref>; Fitzgerald et al., <xref ref-type="bibr" rid="B5">2009</xref>; Pallanti et al., <xref ref-type="bibr" rid="B10">2010</xref>; Rossini et al., <xref ref-type="bibr" rid="B12">2010</xref>).</p><p>We report here results from a pilot single blind double arms controlled study investigating the antidepressant effect, in association with venlafaxine, of active HF (10&#x02009;Hz) LDLPFC rTMS compared to active LF (1&#x02009;Hz) LDLPFC rTMS (150&#x02009;mg) in patient with refractory depressive symptoms.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>Sixteen patients with unipolar major depression according to DSM IV were included through clinical and MINI evaluation (Mini version 4.4). All of them gave their written informed consent before entering the study which was approved by a regional ethical committee. They were aged between 18 and 65 and have not tried venlafaxine for the present depression episode. Patients were recruited at the &#x0201c;Le vinatier&#x0201d; Hospital. At inclusion, all of them present a Montgomery and Asberg (<xref ref-type="bibr" rid="B9">1979</xref>) Depression Rating Scale (MADRS) score &#x0003e;20 despite the prescription of an AD at efficient dose for at least 12&#x02009;weeks. Patients respond to stage 1 of treatment-resistant depression as described in Fava (<xref ref-type="bibr" rid="B4">2003</xref>).</p><p>Prospective patients were screened for contraindications to rTMS, including a history of personal or family seizures, neurological or neurosurgical antecedent, inner ear prosthesis, pacemaker, and anticonvulsive medication. Electroencephalographic and clinical examination was made before the first rTMS sequence.</p><p>Participants were randomly allocated into two groups after 2&#x02009;weeks of wash out period for all medications. Venlafaxine (75&#x02009;mg/day) administration as monotherapy began 3&#x02009;days before the start of rTMS treatment. The day of the first rTMS session, venlafaxine was increased to 150&#x02009;mg on the morning. Then, one group was treated with venlafaxine and HF-rTMS applied over the LDLPFC and the second group was treated with venlafaxine and LF-rTMS applied over the RDLPFC.</p><p>Stimulations were carried out using a MagPro 100 (Medtronic&#x02013;Boulogne&#x02013;France) stimulator system using figure-eight 70-mm coils. Stimulation intensity was 100% of resting motor threshold. Motor threshold was identified as the minimum magnetic field strength required to produce left thenar muscle activation by single transcranial magnetic pulses delivered to the motor cortex for at least 5 of 10 trials. Coil placement was 5&#x02009;cm anterior from motor cortex (international 10&#x02013;20 system). Because two patients withdrew their consent before the start of the trial, the final groups were:</p><list list-type="simple"><list-item><p>&#x02013; High-frequency group (<italic>n</italic>&#x02009;=&#x02009;6): Stimulation frequency was 10&#x02009;Hz. Each patient received 10, 15, or 20 rTMS sessions depending on the response rate after 10 sessions, one session per day (2 or 4&#x02009;weeks). Each daily session consisted in a total of 2000 pulses 40 trains of 5&#x02009;s duration and 30&#x02009;s intertrain intervals.</p></list-item><list-item><p>&#x02013; Low frequency group (<italic>n</italic>&#x02009;=&#x02009;8): Stimulation frequency was 1&#x02009;Hz. Each patient received 10, 15, or 20 rTMS sessions depending on the response rate after 10 sessions, one session per day (2 or 4&#x02009;weeks). Each daily session consisted in a total of 120 pulses of 2 trains of 60&#x02009;s duration and 120&#x02009;s intertrain intervals.</p></list-item></list><p>A psychiatrist blind to group assignment conducted all assessments of patients&#x02019; symptoms. To assess antidepressant effects, we used the 10-items MADRS. We measured MADRS scores at baseline, after 5, 10, 15, and 20 rTMS sessions. Patients who were responders after the first 10 or 15 rTMS sessions (defined as MADRS score &#x0003c;15) did not received more rTMS sessions.</p><sec><title>Analysis</title><p>Comparisons between groups at baseline were assessed using student <italic>t</italic>-tests except for gender (Fischer&#x02019;s chi-square). Statistical analysis was performed at a significant threshold of 0.05 using a repeated measures analysis of variance (ANOVA) on MADRS scores at each assessment times. Number of responders was compared between the groups using Fischer&#x02019;s chi-square test. Statistics were done using the Statistica software.</p></sec></sec><sec><title>Results</title><p>At baseline, the two groups did not significantly differ for age, sex ratio, and for MADRS scores (Table <xref ref-type="table" rid="T1">1</xref>). No adverse event was observed in both groups.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Characteristics of patients throughout the study period</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">1&#x02009;Hz (<italic>n</italic>&#x02009;=&#x02009;8)</th><th align="left" rowspan="1" colspan="1">10&#x02009;Hz (<italic>n</italic>&#x02009;=&#x02009;6)</th><th align="left" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr style="background-color:darkgray;"><td colspan="4" align="left" rowspan="1"><bold>BASELINE CHARACTERISTICS</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">46.1 (16.3)</td><td align="left" rowspan="1" colspan="1">50.8 (9.4)</td><td align="left" rowspan="1" colspan="1">0.54<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (male/female)</td><td align="left" rowspan="1" colspan="1">2/6</td><td align="left" rowspan="1" colspan="1">4/2</td><td align="left" rowspan="1" colspan="1">0.27<sup>&#x02020;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Inpatient/outpatient</td><td align="left" rowspan="1" colspan="1">2/6</td><td align="left" rowspan="1" colspan="1">2/4</td><td align="left" rowspan="1" colspan="1">0.9<sup>*</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">MADRS</td><td align="left" rowspan="1" colspan="1">32.0 (8.0)</td><td align="left" rowspan="1" colspan="1">29.8 (6.9)</td><td align="left" rowspan="1" colspan="1">0.59<sup>*</sup></td></tr><tr style="background-color:darkgray;"><td colspan="4" align="left" rowspan="1"><bold>AFTER 5 rTMS SESSION</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">MADRS decrease (%)</td><td align="left" rowspan="1" colspan="1">&#x02212;15.39 (12.02)</td><td align="left" rowspan="1" colspan="1">&#x02212;19.78 (10.57)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Responders (%)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:darkgray;"><td colspan="4" align="left" rowspan="1"><bold>AFTER 10 rTMS SESSION</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">MADRS decrease (%)</td><td align="left" rowspan="1" colspan="1">&#x02212;22.18 (22.65)</td><td align="left" rowspan="1" colspan="1">&#x02212;34.95 (14.95)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Responders (%)</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:darkgray;"><td colspan="4" align="left" rowspan="1"><bold>AFTER 15 rTMS SESSION</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">MADRS decrease (%)</td><td align="left" rowspan="1" colspan="1">&#x02212;29.72 (34.79)</td><td align="left" rowspan="1" colspan="1">&#x02212;47.11 (19.29)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Responders (%)</td><td align="left" rowspan="1" colspan="1">37.5</td><td align="left" rowspan="1" colspan="1">66.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr style="background-color:darkgray;"><td colspan="4" align="left" rowspan="1"><bold>AFTER 20 rTMS SESSION</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">MADRS decrease (%)</td><td align="left" rowspan="1" colspan="1">&#x02212;51.25 (35.35)</td><td align="left" rowspan="1" colspan="1">&#x02212;52.96 (21.58)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Responders (%)</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">66.7</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><italic>rTMS: repetitive transcranial magnetic stimulation/MADRS: Montgomery&#x02013;Asberg Depression Rating Scale. Results are given as mean (SD)</italic>.</p><fn id="tfn1"><p>*<italic>Student <italic>t</italic>-test; &#x02020;Fischer Chi-square test</italic>.</p></fn><p><italic>Responders were defined as patients with a MADRS score &#x0003c;15</italic>.</p></table-wrap-foot></table-wrap><p>Number of responders did not differ in each group at each assessment (&#x003c7;<sup>2</sup>&#x02009;=&#x02009;0.4; dl&#x02009;=&#x02009;1; <italic>p</italic>&#x02009;=&#x02009;0.57). First responders (MADRS&#x02009;&#x0003c;&#x02009;15) were observed after 10 rTMS session in both groups (Table <xref ref-type="table" rid="T1">1</xref>). More than 50% of patients were responders at the end of the study period (4&#x02009;weeks).</p><p>Effect of treatment (time) was significant in both group [<italic>F</italic><sub>(4,44)</sub>&#x02009;=&#x02009;15.42; <italic>p</italic>&#x02009;&#x0003c;&#x02009;10<sup>&#x02212;7</sup>]. No significant statistical difference was observed for MADRS scores between the two groups [<italic>F</italic><sub>(1,11)</sub>&#x02009;=&#x02009;0.32; <italic>p</italic>&#x02009;=&#x02009;0.58]. We reported no interaction between group (HF or LF) and time [<italic>F</italic><sub>(4,44)</sub>&#x02009;=&#x02009;0.61; <italic>p</italic>&#x02009;=&#x02009;0.66], suggesting that decreases of MADRS scores were comparable in both groups (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Changes in MADRS scores following rTMS sessions in combination with venlafaxine (150&#x02009;mg) in both groups: 1&#x02009;Hz applied over the right dorsolateral prefrontal cortex (DLPFC)/10&#x02009;Hz applied over the left DLPFC</bold>. rTMS: repetitive transcranial magnetic stimulation/MADRS: Montgomery&#x02013;Asberg Depression Rating Scale Results are given as mean and SE.</p></caption><graphic xlink:href="fpsyt-03-00013-g001"/></fig></sec><sec><title>Discussion</title><p>Our results replicate and extend previous findings showing that DLPFC LF-rTMS administered on the right side results in a similar effect compared to left-sided DLPFC HF-rTMS (H&#x000f6;ppner et al., <xref ref-type="bibr" rid="B7">2003</xref>; Isenberg et al., <xref ref-type="bibr" rid="B8">2005</xref>; Stern et al., <xref ref-type="bibr" rid="B16">2007</xref>; Fitzgerald et al., <xref ref-type="bibr" rid="B5">2009</xref>; Pallanti et al., <xref ref-type="bibr" rid="B10">2010</xref>; Rossini et al., <xref ref-type="bibr" rid="B12">2010</xref>). Despite a failure in response to one previous AD, we reported that some patients could be considered as responders only 2&#x02009;weeks after the start of treatment and after 4&#x02009;weeks, more than a half of group could be qualified as responders as defined by a MADRS score &#x0003c;15.</p><p>In combination with venlafaxine (150&#x02009;mg/day), 120 pulses/session of LF-rTMS over the RDLPFC (delivered during 4&#x02009;min) could be as effective as 2000 pulses/session of HF-rTMS over the left DLPFC (delivered during 16&#x02009;min). As the most serious potential side effect of rTMS is seizure, and that LF-rTMS may be protective against it (Theodore et al., <xref ref-type="bibr" rid="B17">2002</xref>), thus, more than saving the user and patient time, LF-rTMS should be a treatment of choice for patients.</p><p>We have observed no relapse during the study period (4&#x02009;weeks) but a follow up period is required before any conclusion on this point. We reported no adverse events in the combination of medication.</p><p>The lack of an arm with placebo venlafaxine in association with active rTMS and of an arm with active venlafaxine and sham rTMS are some limitations of our study. However, it has been reported that 1&#x02009;Hz rTMS is as effective as venlafaxine in the treatment of resistant depression (Bares et al., <xref ref-type="bibr" rid="B2">2009</xref>). Moreover, it is important to note that in a large randomized controlled trial using venlafaxine alone (Rush et al., <xref ref-type="bibr" rid="B14">2006</xref>), with a demographic comparable depressed group, among the patients who had a remission (24.8% of the sample), the mean time to remission was 5.5&#x02009;&#x000b1;&#x02009;4.7&#x02009;weeks (median, 4.2). We reported more than 50% decrease of MADRS score after 4&#x02009;weeks of treatment while a 30% decrease of HDRS was reported in a large study investigating the impact of venlafaxine after previous AD failure (Baldomero et al., <xref ref-type="bibr" rid="B1">2005</xref>). On the other hand, as it seems to be the case in our results, Rumi et al. (<xref ref-type="bibr" rid="B13">2005</xref>) have reported that in add-on therapy rTMS may be able to accelerate the delay efficacy of AD.</p><p>In conclusion, although limited by small sample size and lack of venlafaxine placebo arm, in a sample of patients who have not responded to one trial of antidepressant medication, in combination with venlafaxine 150&#x02009;mg/day, right-sided LF-rTMS seems as effective as left-sided HF-rTMS. In order to investigate the real impact of LF-rTMS without any antidepressant treatment compared to rTMS in add-on therapy with venlafaxine and to venlafaxine alone, we have started a large multicentric study (clinicaltrials.gov; NCT00714090).</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>This work was supported by the Conseil Scientifique de la Recherche (CSR), CH le Vinatier. Mondino Marine held a doctoral fellowship from la R&#x000e9;gion Rh&#x000f4;ne-Alpes.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldomero</surname><given-names>E. B.</given-names></name><name><surname>Ubago</surname><given-names>J. G.</given-names></name><name><surname>Cerc&#x000f3;s</surname><given-names>C. L.</given-names></name><name><surname>Ruiloba</surname><given-names>J. V.</given-names></name><name><surname>Calvo</surname><given-names>C. G.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>R. P.</given-names></name></person-group> (<year>2005</year>). <article-title>Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study</article-title>. <source>Depress. Anxiety</source>
<volume>22</volume>, <fpage>68</fpage>&#x02013;<lpage>76</lpage><pub-id pub-id-type="doi">10.1002/da.20080</pub-id><pub-id pub-id-type="pmid">16094658</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bares</surname><given-names>M.</given-names></name><name><surname>Kopecek</surname><given-names>M.</given-names></name><name><surname>Novak</surname><given-names>T.</given-names></name><name><surname>Stopkova</surname><given-names>P.</given-names></name><name><surname>Sos</surname><given-names>P.</given-names></name><name><surname>Kozeny</surname><given-names>J.</given-names></name><name><surname>Brunovsky</surname><given-names>M.</given-names></name><name><surname>H&#x000f6;schl</surname><given-names>C.</given-names></name></person-group> (<year>2009</year>). <article-title>Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study</article-title>. <source>J. Affect. Disord.</source>
<volume>118</volume>, <fpage>94</fpage>&#x02013;<lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2009.01.032</pub-id><pub-id pub-id-type="pmid">19249105</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunelin</surname><given-names>J.</given-names></name><name><surname>Poulet</surname><given-names>E.</given-names></name><name><surname>Boeuve</surname><given-names>C.</given-names></name><name><surname>Zeroug-Vial</surname><given-names>H.</given-names></name><name><surname>D&#x02019;Amato</surname><given-names>T.</given-names></name><name><surname>Saoud</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Efficacy of repetitive transcranial magnetic stimulation (rTMS) in major depression</article-title>. <source>Encephale</source>
<volume>33</volume>, <fpage>126</fpage>&#x02013;<lpage>134</lpage><pub-id pub-id-type="doi">10.1016/S0013-7006(07)91542-0</pub-id><pub-id pub-id-type="pmid">17675907</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Diagnosis and definition of treatment-resistant depression</article-title>. <source>Biol. Psychiatry</source>
<volume>53</volume>, <fpage>649</fpage>&#x02013;<lpage>659</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(03)00231-2</pub-id><pub-id pub-id-type="pmid">12706951</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>P. B.</given-names></name><name><surname>Hoy</surname><given-names>K.</given-names></name><name><surname>Daskalakis</surname><given-names>Z. J.</given-names></name><name><surname>Kulkarni</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>A randomized trial of the anti-depressant effects of low- and high-frequency transcranial magnetic stimulation in treatment-resistant depression</article-title>. <source>Depress. Anxiety</source>
<volume>26</volume>, <fpage>229</fpage>&#x02013;<lpage>234</lpage><pub-id pub-id-type="doi">10.1002/da.20454</pub-id><pub-id pub-id-type="pmid">19105212</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>M. S.</given-names></name><name><surname>Lisanby</surname><given-names>S. H.</given-names></name><name><surname>Avery</surname><given-names>D.</given-names></name><name><surname>McDonald</surname><given-names>W. M.</given-names></name><name><surname>Durkalski</surname><given-names>V.</given-names></name><name><surname>Pavlicova</surname><given-names>M.</given-names></name><name><surname>Anderson</surname><given-names>B.</given-names></name><name><surname>Nahas</surname><given-names>Z.</given-names></name><name><surname>Bulow</surname><given-names>P.</given-names></name><name><surname>Zarkowski</surname><given-names>P.</given-names></name><name><surname>Holtzheimer</surname><given-names>P. E.</given-names><suffix>III</suffix></name><name><surname>Schwartz</surname><given-names>T.</given-names></name><name><surname>Sackeim</surname><given-names>H. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial</article-title>. <source>Arch. Gen. Psychiatry</source>
<volume>67</volume>, <fpage>507</fpage>&#x02013;<lpage>516</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.46</pub-id><pub-id pub-id-type="pmid">20439832</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;ppner</surname><given-names>J.</given-names></name><name><surname>Schulz</surname><given-names>M.</given-names></name><name><surname>Irmisch</surname><given-names>G.</given-names></name><name><surname>Mau</surname><given-names>R.</given-names></name><name><surname>Schl&#x000e4;fke</surname><given-names>D.</given-names></name><name><surname>Richter</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>Antidepressant efficacy of two different rTMS procedures. High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation</article-title>. <source>Eur. Arch. Psychiatry Clin. Neurosci.</source>
<volume>253</volume>, <fpage>103</fpage>&#x02013;<lpage>109</lpage><pub-id pub-id-type="pmid">12799750</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isenberg</surname><given-names>K.</given-names></name><name><surname>Downs</surname><given-names>D.</given-names></name><name><surname>Pierce</surname><given-names>K.</given-names></name><name><surname>Svarakic</surname><given-names>D.</given-names></name><name><surname>Garcia</surname><given-names>K.</given-names></name><name><surname>Jarvis</surname><given-names>M.</given-names></name><name><surname>North</surname><given-names>C.</given-names></name><name><surname>Kormos</surname><given-names>T. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Low frequency rTMS stimulation of the right frontal cortex is as effective as high frequency rTMS stimulation of the left frontal cortex for antidepressant-free, treatment-resistant depressed patients</article-title>. <source>Ann. Clin. Psychiatry</source>
<volume>17</volume>, <fpage>153</fpage>&#x02013;<lpage>159</lpage><pub-id pub-id-type="doi">10.1080/10401230591002110</pub-id><pub-id pub-id-type="pmid">16433057</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>S. A.</given-names></name><name><surname>Asberg</surname><given-names>M.</given-names></name></person-group> (<year>1979</year>). <article-title>A new depression scale designed to be sensitive to change</article-title>. <source>Br. J. Psychiatry</source>
<volume>134</volume>, <fpage>383</fpage>&#x02013;<lpage>389</lpage><pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallanti</surname><given-names>S.</given-names></name><name><surname>Bernardi</surname><given-names>S.</given-names></name><name><surname>Di Rollo</surname><given-names>A.</given-names></name><name><surname>Antonini</surname><given-names>S.</given-names></name><name><surname>Quercioli</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression?</article-title>
<source>Neuroscience</source>
<volume>167</volume>, <fpage>323</fpage>&#x02013;<lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.01.063</pub-id><pub-id pub-id-type="pmid">20144692</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulet</surname><given-names>E.</given-names></name><name><surname>Brunelin</surname><given-names>J.</given-names></name><name><surname>Boeuve</surname><given-names>C.</given-names></name><name><surname>Lerond</surname><given-names>J.</given-names></name><name><surname>D&#x02019;Amato</surname><given-names>T.</given-names></name><name><surname>Dalery</surname><given-names>J.</given-names></name><name><surname>Saoud</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment</article-title>. <source>Eur. Psychiatry</source>
<volume>19</volume>, <fpage>382</fpage>&#x02013;<lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2004.06.021</pub-id><pub-id pub-id-type="pmid">15363481</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>D.</given-names></name><name><surname>Lucca</surname><given-names>A.</given-names></name><name><surname>Magri</surname><given-names>L.</given-names></name><name><surname>Malaguti</surname><given-names>A.</given-names></name><name><surname>Smeraldi</surname><given-names>E.</given-names></name><name><surname>Colombo</surname><given-names>C.</given-names></name><name><surname>Zanardi</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>A symptom-specific analysis of the effect of high-frequency left or low-frequency right transcranial magnetic stimulation over the dorsolateral prefrontal cortex in major depression</article-title>. <source>Neuropsychobiology</source>
<volume>62</volume>, <fpage>91</fpage>&#x02013;<lpage>97</lpage><pub-id pub-id-type="doi">10.1159/000315439</pub-id><pub-id pub-id-type="pmid">20523080</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rumi</surname><given-names>D. O.</given-names></name><name><surname>Gattaz</surname><given-names>W. F.</given-names></name><name><surname>Rigonatti</surname><given-names>S. P.</given-names></name><name><surname>Rosa</surname><given-names>M. A.</given-names></name><name><surname>Fregni</surname><given-names>F.</given-names></name><name><surname>Rosa</surname><given-names>M. O.</given-names></name><name><surname>Mansur</surname><given-names>C.</given-names></name><name><surname>Myczkowski</surname><given-names>M. L.</given-names></name><name><surname>Moreno</surname><given-names>R. A.</given-names></name><name><surname>Marcolin</surname><given-names>M. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study</article-title>. <source>Biol. Psychiatry</source>
<volume>57</volume>, <fpage>162</fpage>&#x02013;<lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.10.029</pub-id><pub-id pub-id-type="pmid">15652875</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>A. J.</given-names></name><name><surname>Trivedi</surname><given-names>M. H.</given-names></name><name><surname>Wisniewski</surname><given-names>S. R.</given-names></name><name><surname>Stewart</surname><given-names>J. W.</given-names></name><name><surname>Nierenberg</surname><given-names>A. A.</given-names></name><name><surname>Thase</surname><given-names>M. E.</given-names></name><name><surname>Ritz</surname><given-names>L.</given-names></name><name><surname>Biggs</surname><given-names>M. M.</given-names></name><name><surname>Warden</surname><given-names>D.</given-names></name><name><surname>Luther</surname><given-names>J. F.</given-names></name><name><surname>Shores-Wilson</surname><given-names>K.</given-names></name><name><surname>Niederehe</surname><given-names>G.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name><collab>for the STAR*D Study Team</collab></person-group> (<year>2006</year>). <article-title>Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression</article-title>. <source>N. Engl. J. Med.</source>
<volume>354</volume>, <fpage>1231</fpage>&#x02013;<lpage>1242</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052963</pub-id><pub-id pub-id-type="pmid">16554525</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffens</surname><given-names>D. C.</given-names></name><name><surname>Krishnan</surname><given-names>K. R.</given-names></name><name><surname>Helms</surname><given-names>M. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis</article-title>. <source>Depress. Anxiety</source>
<volume>6</volume>, <fpage>10</fpage>&#x02013;<lpage>18</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1520-6394(1997)6:1&#x0003c;10::AID-DA2&#x0003e;3.0.CO;2-9</pub-id><pub-id pub-id-type="pmid">9394870</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>W. M.</given-names></name><name><surname>Tormos</surname><given-names>J. M.</given-names></name><name><surname>Press</surname><given-names>D. Z.</given-names></name><name><surname>Pearlman</surname><given-names>C.</given-names></name><name><surname>Pascual-Leone</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Antidepressant effects of high and low frequency repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex: a double-blind, randomized, placebo-controlled trial</article-title>. <source>J. Neuropsychiatry Clin. Neurosci.</source>
<volume>19</volume>, <fpage>179</fpage>&#x02013;<lpage>186</lpage><pub-id pub-id-type="doi">10.1176/appi.neuropsych.19.2.179</pub-id><pub-id pub-id-type="pmid">17431065</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodore</surname><given-names>W. H.</given-names></name><name><surname>Hunter</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Vega-Bermudez</surname><given-names>F.</given-names></name><name><surname>Boroojerdi</surname><given-names>B.</given-names></name><name><surname>Reeves-Tyer</surname><given-names>P.</given-names></name><name><surname>Werhahn</surname><given-names>K.</given-names></name><name><surname>Kelley</surname><given-names>K. R.</given-names></name><name><surname>Cohen</surname><given-names>L.</given-names></name></person-group> (<year>2002</year>). <article-title>Transcranial magnetic stimulation for the treatment of seizures: a controlled study</article-title>. <source>Neurology</source>
<volume>59</volume>, <fpage>560</fpage>&#x02013;<lpage>562</lpage><pub-id pub-id-type="pmid">12196649</pub-id></mixed-citation></ref></ref-list></back></article>